Subscribe To
Biovie updates investors on its alzheimer's and parkinson's clinical programs
BioVie Inc (NASDAQ:BIVI) said it has made significant progress with its clinical programs, including its drug candidate NE3107 showing a clinically me...
December 7, 2022, 9:08 am
Why biovie's shares tumbled tuesday
The clinical-stage biotech released data on its prospective alzheimer's therapy....
December 6, 2022, 1:54 pm
Anavex life sciences: the little company that did
Anavex's 2-73/blarcamesine produced significant reductions in cognitive decline in early alzheimer's di...
December 6, 2022, 12:51 pm
Biovie: treating alzheimer's, parkinson's, and potentially reversing the biological clock
BioVie's NE3107 has now shown improvement of cognition and function on different alzheimer's rating sca...
December 6, 2022, 12:00 pm
Biovie announces positive results from two phase 2 trials assessing ne3107's potential in parkinson's disease and alzheimer's disease
BioVie Inc (NASDAQ:BIVI) has announced positive results from two Phase 2 trials assessing NE3107's potential in Parkinson's Disease (PD) and ...
December 6, 2022, 6:56 am
Johnson & johnson: alzheimer's disease pipeline could dominate
Johnson & Johnson selected a vaccine to take to Phase 3. Another rival amyloid beta antibody could appear on the market next year....
December 5, 2022, 4:56 pm
Anavex's (avxl) lead alzheimer's drug meets study goal
Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function ...
December 5, 2022, 2:18 pm
Is anavex life sciences a smart stock to buy now?
The company's alzheimer's disease drug just succeeded in a clinical trial. Or did it?...
December 3, 2022, 5:23 am
Why anavex life sciences stock is surging today
The biotech reported positive results from a phase 2b/3 study of its lead alzheimer's disease candidate...
December 2, 2022, 11:37 am
Anavex catapults on alzheimer's results — but math question clouds the data
Anavex Life Sciences said its experimental alzheimer's treatment met the goals of a midstage study, lea...
December 2, 2022, 10:41 am
Why shares of vaxxinity soared this week
Positive news regarding a different company's alzheimer's treatment may have helped Vaxxinity....
December 2, 2022, 5:30 am
Lilly's (lly) donanemab betters biogen's alzheimer's drug
Data from a phase III early symptomatic alzheimer's disease study shows that Eli Lilly's (LLY) donanema...
December 1, 2022, 9:47 am
Lilly said its alzheimer's drug clears more amyloid plaque than aduhelm
Eli Lilly & Co. LLY, +1.96% said Wednesday night that its experimental alzheimer's treatment did a bett...
December 1, 2022, 8:05 am
Experimental drug lecanemab may be a landmark breakthrough in battle against alzheimer's
Yahoo Finance's Anjalee Khemlani discusses positive news around an alzheimer's drug, plus reports that ...
November 30, 2022, 1:44 pm
5 things to know about the new alzheimer's drug — including why it may be risky for people who take blood thinners
Shares of Eisai and Biogen did not move dramatically after the drug companies reported the full results of the clinical trial for their experimental <...
November 30, 2022, 11:38 am
Biogen's (biib) lecanemab shows benefit but with side effects
Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of ...
November 30, 2022, 10:32 am
Why this new alzheimer's update is likely to spark a debate for biogen investors
Biogen stock surged Wednesday after partner Eisai unveiled alzheimer's treatment test results that two ...
November 30, 2022, 10:14 am
Biib stock alert: what the latest alzheimer's drug data means for biogen
Biogen (NASDAQ: BIIB ) stock is on the move Wednesday after the company provided the latest update on its alzh...
November 30, 2022, 10:00 am
Biogen stock is surging today: what's going on? - biogen (nasdaq:biib)
Biogen Inc (NASDAQ: BIIB) shares are trading higher Wednesday after the company announced positive trial results for its experimental ...
November 30, 2022, 9:16 am
Biogen stock up 3% premarket after update on alzheimer's treatment; stifel reiterates buy rating
Biogen Inc. stock BIIB, -0.17% rose 3% in premarket trade Wednesday, after a new study was unveiled late Tuesday that showed the company's experimenta...
November 30, 2022, 6:48 am